Innovations in Low-Risk MDS with Dr. Jan Bewersdorf image

Innovations in Low-Risk MDS with Dr. Jan Bewersdorf

Can't make it to the event?
We send a recording to all registered participants of the event!
Aug 11, 2026
12:30PM - 01:30PM EDT
Online Event
Overview

Join the HealthTree Foundation for a webinar on Low-Risk MDS care and recent treatment innovations.

Featured Speaker: Dr. Jan Bewersdorf (MDS Expert)

Why Attend?

  1. Learn about the latest advancements in Low-Risk MDS care.

  2. Get your questions answered during a live Q&A session.

  3. Can't attend live? Register anyway to receive the event recording directly to your inbox.

Agenda
12:30 PM
Introduction
Dalton Bean

Dalton introduces the agenda for the event and the speaker Jan Bewersdorf, MD, FACP

12:35 PM
Presentation
Jan Bewersdorf, MD, FACP

Dr. Bewersdorf shares innovations in low- risk MDS patients

1:05 PM
Questions & Answers
Audience

Come prepared to learn and ready to ask questions!

Speakers & Moderators
Healthtree contact Dalton Bean

Dalton Bean

Dalton joined HealthTree in 2024 as the MPNs and MDS Program Manager. He is passionate about helping patients gain a better understanding of their health and treatment and sees it as a way to help empower individuals and their families who are affected by these diseases. Prior to joining HealthTree Dalton earned a Master’s Degree in Oncological Sciences while studying various different blood cancers. When not interacting with patients he is an avid snowboarder and hiker.
Healthtree contact Jan Bewersdorf, MD, FACP

Jan Bewersdorf, MD, FACP

Dr. Jan Philipp Bewersdorf is an Assistant Professor of Medicine (Hematology) at Yale University. Following medical school training in Germany, he completed his Internal Medicine training at Yale - New Haven Hospital. After completion of residency, Dr. Bewersdorf pursued his fellowship in Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center in New York before joining the faculty at Yale in July 2024. Dr. Bewersdorf is board-certified in Internal Medicine, Medical Oncology and Hematology. His career as a clinician-scientist has been dedicated to myeloid malignancies spanning from myeloproliferative neoplasms to myelodysplastic syndromes and acute myeloid leukemia. Dr. Bewersdorf's work aims to combine basic and translational research with clinical and outcomes research to study those disorders from multiple angles. Inspired by the privilege of taking care of patients with myeloid neoplasms, he strives to advance patient care by conducting innovative clinical trials with a strong correlative component in collaboration with laboratory-based colleagues. He has developed and co-led several early phase clinical trials in myeloid malignancies and his research efforts have led to over 130 peer-reviewed publications to date including first-author publications in Lancet, Blood, Leukemia, and Lancet Haematology. Dr. Bewersdorf has received several prestigious awards including the Edwards P. Evans Young Investigator Award, the Mortimer Lacher Fellowship from the Lymphoma Foundation, and multiple other achievement awards. He also serves on the editorial board and is a reviewer of several important hematology and oncology journals.